Aspect Medical Systems Appoints Ralph Germscheid Vice President of Sales

Accomplished Sales Executive Joins Consciousness Monitoring Market Leader

Jul 24, 2000, 01:00 ET from Aspect Medical Systems, Inc.

    NEWTON, Mass., July 24 /PRNewswire/ -- Aspect Medical Systems, Inc.
 (Nasdaq:   ASPM), the world's leading provider of consciousness monitoring
 technology, has named Ralph Germscheid vice president of sales, announced
 Nassib Chamoun, president and CEO of Aspect.  Germscheid brings more than 20
 years of sales and sales management experience in the anesthesia market.  He
 joined Nellcor (acquired by Mallinckrodt in 1998) more than 16 years ago, and
 began shortly after the company's introduction of pulse oximetry into the
 anesthesia market.  He will be responsible for directing Aspect's sales and
 distribution organization to expand market penetration of the company's
 proprietary BIS monitoring system.
     ( Photo: )
     "Ralph brings a strong record of success in conceptual selling of new
 technologies to the anesthesia community," said Chamoun.  "His role in
 developing the market for pulse oximetry and helping to establish the
 technology as a standard of care in anesthesia is directly applicable to
 Aspect's mission.  Moreover, Ralph's charismatic style and proven leadership
 position him well to quickly become an integral part of our organization and
 further increase the size and scope of our presence in the marketplace."
     Germscheid joins Aspect with a track record of exceeding sales objectives
 at Nellcor, Nellcor Puritan Bennett and Mallinckrodt.  For the past two years,
 he served as vice president of sales for Mallinckrodt's alternate care
 business managing a large team of sales representatives, as well as corporate
 accounts and customer service.  In this position, Germscheid spearheaded
 programs to integrate and expand the organization, such as the design and
 implementation of a strategic sales information system.  In addition, he
 established a national network of independent manufacturers representatives to
 expand product availability for customers.  Prior to Mallinckrodt's
 acquisition of Nellcor Puritan Bennett, Germscheid was western area sales
 manager responsible for sales and clinical personnel in 26 states.
     "Aspect is an innovative company with an energetic spirit and a technology
 that truly makes a difference in patient care," Germscheid stated.  "I look
 forward to leading and empowering the field sales organization to accelerate
 the market penetration of BIS technology and further improve anesthesia
     About BIS Monitoring
     Developed in collaboration with leading anesthesiologists, BIS monitoring
 enables clinicians to assess and manage the effects of drug dosing in the
 operating room and intensive care settings.
     BIS monitoring uses a sensor placed on the forehead to capture EEG
 signals, which are translated into a single number ranging from 100 (for wide
 awake) to zero (indicating the absence of brain electrical activity).  As a
 result, BIS monitoring allows clinicians to better determine the amount of
 drug that each patient needs, thereby helping to prevent over-dosing and
 under-dosing.  In the OR, this enables patients to have a faster and higher
 quality recovery with fewer post-operative side effects.  These benefits are
 achieved while the provider is able to continuously assess the risk of patient
 awareness during surgery.  In critical care settings, BIS monitoring is used
 to titrate sedatives and help minimize the clinical and economic consequences
 of under-sedation and over-sedation.
     BIS technology is available in Aspect's A-2000(TM) BIS monitor and has
 been licensed for integration into the majority of patient monitoring and
 anesthesia delivery systems, including Agilent Technologies, Drager, GE
 Marquette, Nihon Kohden and Spacelabs Medical.
     Since its commercial introduction in October 1996, more than 900
 healthcare facilities nationwide have adopted the BIS monitor, with more than
 8,200 monitors in use and over 1,800,000 patients monitored across the globe.
 To date, more than 450 peer-reviewed articles and abstracts have been
 published that document the efficacy, limitations and outcomes benefits of the
 BIS system.
     About Aspect Medical Systems, Inc.
     Aspect Medical Systems, Inc. develops noninvasive monitoring systems to
 improve the cost effectiveness and quality of patient care.  The company's
 systems utilize innovative, patented, digital signal processing software
 linked to proprietary sensors. Aspect meets ISO 9001 certification
 requirements. For more information, visit the company's Web site at
     Certain statements in this release are forward looking and may involve
 risk and uncertainties, including statements with respect to market acceptance
 and market penetration.  Among the factors that could cause actual results to
 differ materially from those indicated by such forward-looking statements are
 the results of clinical trials, the Company's ability to successfully
 commercialize its products and products under development, the company's
 ability to achieve and maintain regulatory approval of products under
 development, the scope of the company's patent protection and other risks
 included under the heading "Risk Factors" in the company's Quarterly Report on
 Form 10-Q filed on May 15, 2000, filed with the Securities and Exchange
     Bispectral Index and BIS are registered trademarks of Aspect Medical
 Systems, Inc. A-2000 is a trademark of Aspect Medical Systems, Inc.
      Contact:  Lorie Fiber/Courtney Walker
                Fischer & Partners, Inc.
                310-577-7870 ext. 109/113

SOURCE Aspect Medical Systems, Inc.